Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis”...
NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised...
NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...
Ionis Pharmaceuticals: Q2 Earnings Snapshot
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027. “As...
- TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – ...
Barchart Research What to Expect from IONS Earnings IONS Generated July 28, 2026 Current Price $55.30 EPS Estimate $$-1.11 Consensus Rating Moderate Buy Average Move 3.03% Ionis Faces Its Easiest Earnings...
SAN FRANCISCO , July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. ( NASDAQ: IONS ) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial...
NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...
NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...